Connect with us
neuralink-patient-registry-volunteers neuralink-patient-registry-volunteers

News

Neuralink hopes to have first its human trials next year pending FDA approval

(Credit: NeuraLink)

Published

on

Elon Musk appeared for a short but productive interview at the Wall Street Journal’s (WSJ) CEO Council Summit on Tuesday, December 7. Musk provided updates on each of his companies’ most interesting projects, including Tesla’s Cybertruck, SpaceX’s Starship, and Neuralink’s brain implant. 

The CEO of many forward-thinking companies seemed very optimistic about Neuralink in particular and its potential in the future. At the summit, Musk stated that Neuralink hopes to start human trials in 2022, pending FDA approval. 

“We hope to have this in our first humans, which will be people who have severe spinal cord injuries like tetraplegics, quadriplegics next year pending FDA approval. And, I should say, our standards for implanting the device are substantially higher than what the FDA requires. Just as our standards for safety with Tesla are much higher than what the US government requires,” the Neuralink CEO said. 

Tetraplegia, also known as quadriplegia, is a form of paralysis that affects both arms and legs. Tetraplegia-causing injury can vary in severity. Neuralink has created a device called the N1 Link, intended to help patients like those who are tetraplegic.

The N1 Link is a 1024 channel device that Neuralink made for patients’ therapeutic use. Once the device is implanted into a patient’s brain, it is expected to invisibly transmit data via a wireless connection. Neuralink demoed the outcome of a successfully implanted N1 Link in its video featuring a Macaque monkey named Pager, playing Pong with his mind.

Elon Musk is cautiously optimistic about the N1 Link’s future. He believes Neuralink’s device could help people with severe spinal cord injuries. 

Advertisement

“I think it’s something pretty cool, and I do want to say that I’m very, emphasis on cautiously, optimistic about this. I think we have a chance with Neuralink of being able to restore full body functionality to someone who has a spinal cord injury.

“Meaning, I think we have a chance—I emphasize a chance—of being able to allow someone who cannot walk or use their arms to be able to walk again naturally. It’s a super big deal, and I don’t want to raise hopes unreasonably. But I’m increasingly convinced that this can be done,” Musk said. 

For now, Neuralink is focusing on the N1 Link’s potential to help quadriplegics regain their digital freedom by giving them the ability to interact with their computers or phones in a high bandwidth and naturalistic way. In July, the company announced a Series C funding round of $205 million, which will take the N1 Link to market. Part of the funds will also accelerate research and development in other products.

Elon Musk’s short-term goal for Neuralink is to help people with brain injuries. Neuralink’s long-term goal is to reduce AI risk to humanity. 

Watch Elon Musk’s WSJ interview below!

Advertisement

The Teslarati team would appreciate hearing from you. If you have any tips, reach out to me at maria@teslarati.com or via Twitter @Writer_01001101.

Maria--aka "M"-- is an experienced writer and book editor. She's written about several topics including health, tech, and politics. As a book editor, she's worked with authors who write Sci-Fi, Romance, and Dark Fantasy. M loves hearing from TESLARATI readers. If you have any tips or article ideas, contact her at maria@teslarati.com or via X, @Writer_01001101.

Advertisement
Comments

News

Robots like Tesla Optimus are a $5 trillion opportunity: analyst

This massive opportunity could be tapped by Tesla, thanks to its Optimus humanoid robot.

Published

on

tesla-optimus-pilot-production-line-fremont-factory
Credit: Tesla

Morgan Stanley analysts have estimated that the humanoid robot market could offer a $5 trillion opportunity by the middle of the century. This massive opportunity could be tapped by Tesla, thanks to its Optimus humanoid robot.

The analysts, however, noted that the humanoid robots will likely be mostly used in industrial and commercial deployments.

The Estimates

Estimates from Morgan Stanley analysts point to humanoid robots hitting $5 trillion in global revenue by 2050. This, the analysts noted, would be about double the total revenue of the 20 largest automakers in 2024. In 2050, Morgan Stanley analysts estimated that there might be about 1 billion humanoid robots deployed.

As noted in a report from Investing.com, the shift to humanoid robots would be gradual. By 2035, the analysts estimated that just about 13 million humanoid robots will be in use, most of which will be used in industrial and commercial settings. Even in 2050, when the analysts estimated that 1 billion humanoid robots will be in use, an estimated 90% might still be used in industrial and commercial settings.

The advent of humanoid robots will likely be felt in the labor sector, Morgan Stanley analysts noted. By 2030, the analysts noted that humanoid robots could replace about 40,000 jobs. Just ten years later, in 2040, the number of jobs that robots could take over could balloon to 8.4 million. By 2050, the analysts noted that 62.7 million humans may end up watching humanoid robots do their jobs.

Advertisement

Tesla Potential

Morgan Stanley noted that companies like Tesla, which control the “brains, bodies, branding and ecosystems” of the humanoid robots, would be able to offer the highest value. This is good news for Tesla’s Optimus program, as it is a product that is designed to be produced at an extreme scale. During the Q1 2025 All Hands meeting, Elon Musk reiterated the idea that Optimus could very well become the biggest product of all time.

Most importantly, Musk also stated that Tesla is internally aiming to acquire enough resources to produce 10,000 to 12,000 Optimus robots this year. But even if Tesla just manages half of this number, or about 5,000 Optimus robots this year, it would already be impressive.

“Even 5,000 robots, that’s the size of a Roman legion, FYI, which is like a little scary thought. Like a whole legion of robots, I’ll be like ‘whoa.’ But I think we will literally build a legion, at least one legion of robots this year, and then probably 10 legions next year. I think it’s kind of a cool unit, you know? Units of legion. So probably 50,000-ish next year,” Musk stated.

Continue Reading

News

SpaceX set to launch Axiom’s mission for diabetes research on the ISS

Axiom’s Ax-4 will test CGMs & insulin stability in microgravity—potentially reshaping diabetes care for Earth & future astronauts.

Published

on

(Credit: SpaceX)

Axiom Space’s Ax-4 mission is set to launch on a SpaceX Falcon 9 rocket. Ax-4 will advance diabetes research in microgravity, marking a milestone for astronaut health.

Axiom Space’s fourth crewed mission is scheduled to launch with SpaceX on May 29 from NASA’s Kennedy Space Center in Florida. The Ax-4 mission will carry a diverse crew and a record-breaking scientific payload to the International Space Station (ISS).

The Ax-4 crew is led by Axiom’s Peggy Whitson and includes Shubhanshu Shukla from India, Sławosz Uznański from the European Space Agency, and Tibor Kapu from Hungary. The mission represents firsts for India, Hungary, and Poland, with Uznański being Poland’s first astronaut in over 40 years.

Ax-4 will conduct nearly 60 science investigations from 31 countries during its two-week ISS stay. A key focus is the “Suite Ride” initiative, a collaboration with Burjeel Holdings to study diabetes management in microgravity.

“The effort marks a significant milestone in the long-term goal of supporting future astronauts with insulin-dependent diabetes (IDDM), a condition historically deemed disqualifying for spaceflight,” Axiom noted. The mission will test Continuous Glucose Monitors (CGMs) and insulin stability to assess their performance in space.

Advertisement

Axiom explained that testing the behavior of CGMs and insulin delivery technologies in microgravity and observing circadian rhythm disruption could help diabetes experts understand how CGMs and insulin pens can improve diabetes monitoring and care in remote or underserved areas on Earth. The research could benefit diabetes management in isolated regions like oil rigs or rural areas.

The mission’s findings on insulin exposure and CGM performance could pave the way for astronauts with diabetes to safely participate in spaceflight. As Axiom and SpaceX push boundaries, Ax-4’s diabetes research underscores the potential for space-based innovations to transform healthcare on Earth and beyond.

Continue Reading

Energy

Tesla Energy celebrates one decade of sustainability

Tesla Energy has gone far since its early days, and it is now becoming a progressively bigger part of the company.

Published

on

(Credit: Tesla)

Tesla Energy recently celebrated its 10th anniversary with a dedicated video showcasing several of its milestones over the past decade.

Tesla Energy has gone far since its early days, and it is now becoming a progressively bigger part of the company.

Tesla Energy Early Days

When Elon Musk launched Tesla Energy in 2015, he noted that the business is a fundamental transformation of how the world works. To start, Tesla Energy offered the Powerwall, a 7 kWh/10 kWh home battery system, and the Powerpack, a grid-capable 100 kWh battery block that is designed for scalability. A few days after the products’ launch, Musk noted that Tesla had received 38,000 reservations for the Powerwall and 2,500 reservations for the Powerpack

Tesla Energy’s beginnings would herald its quiet growth, with the company later announcing products like the Solar Roof tile, which is yet to be ramped, and the successor to the Powerwall, the 13.5 kWh Powerwall 2. In recent years, Tesla Energy also launched its Powerwall 3 home battery and the massive Megapack, a 3.9 MWh monster of a battery unit that has become the backbone for energy storage systems across the globe.

Key Milestones

As noted by Tesla Energy in its recent video, it has now established facilities that allow the company to manufacture 20,000 units of the Megapack every year, which should help grow the 23 GWh worth of Megapacks that have already been deployed globally. 

Advertisement

The Powerwall remains a desirable home battery as well, with more than 850,000 units installed worldwide. These translate to 12 GWh of residential entry storage delivered to date. Just like the Megapack, Tesla is also ramping its production of the Powerwall, allowing the division to grow even more.

Tesla Energy’s Role

While Tesla Energy does not catch as much headlines as the company’s electric vehicle businesses, its contributions to the company’s bottom line have been growing. In the first quarter of 2025 alone, Tesla Energy deployed 10.4 GWh of energy storage products. Powerwall deployments also crossed 1 GWh in one quarter for the first time. As per Tesla in its Q1 2025 Update Letter, the gross margin for the Energy division has improved sequentially as well.

Continue Reading

Trending